Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/22653
Title: | Risk factors and complications of intracranial pressure monitoring with a fiberoptic device |
Authors: | Uludağ Üniversitesi/Tıp Fakültesi/Nöroşirürji Anabilim Dalı. Uludağ Üniversitesi/Tıp Fakültesi/Anestezi ve Reanimasyon Anabilim Dalı. 0000-0003-3633-7919 Bekar, Ahmet Doğan, Şeref Abaş, Faruk Caner, Burcu Korfalı, Gülşen Kocaeli, Hasan Yılmazlar, Selçuk Korfalı, Ender Caner, Burcu AAI-6531-2021 AAH-5070-2021 7102693077 6603677218 8546184300 25027089000 6701462594 6603500567 6603059483 7004641343 |
Keywords: | Complications Fiberoptic device Intracranial pressure Monitoring Brain-tissue pressure Head-injured patients Clinical-evaluation Infectious complications Aggressive treatment Experience Duration Neurosciences & neurology |
Issue Date: | Feb-2009 |
Publisher: | Elsevier |
Citation: | Bekar, A. vd. (2009). "Risk factors and complications of intracranial pressure monitoring with a fiberoptic device". Journal of Clinical Neuroscience, 16(2), 236-240. |
Abstract: | We prospectively investigated the complications associated with intraparenchymal intracranial pressure (ICP) monitoring using the Camino intracranial pressure device. A fiberoptic ICP monitoring transducer was implanted in 631 patients. About half of the patients (n = 303) also received an external ventricular drainage set (EVDS). The durations (mean +/- SD) of ICP monitoring in patients without and with an EVDS were 6.5 +/- 4.4 and 7.3 +/- 5.1 days, respectively. Infection occurred in 6 patients with only an ICP transducer (6/328, 1.8%) and 24 patients with an EVDS also (24/303, 7.9%). The duration of monitoring had no effect on infection, whereas the use of an EVDS for more than 9 days increased infection risk by 5.11 times. Other complications included transducer disconnection (2.37%), epidural hematoma (0.47%), contusion (0.47%), defective probe (0.31%), broken transducer (0.31%), dislocation of the fixation screw (0.15%), and intraparenchymal hematoma (0.15%). In conclusion, intraparenchymal ICP monitoring systems can be safely used in patients who either have, or are at risk of developing, increased ICP. |
URI: | https://doi.org/10.1016/j.jocn.2008.02.008 https://www.sciencedirect.com/science/article/pii/S0967586808001082 http://hdl.handle.net/11452/22653 |
ISSN: | 0967-5868 |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.